<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-10-02-2026-shutterstock_2427838693-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-10-02-2026-shutterstock_2427838693-430x241.jpg"/></p>
<p>通过这一安排，武田将获得 Iambic 的 NeuralPLexer 模型，以预测蛋白质 - 配体复合物。来源：Veroniksha / Shutterstock.com。</p>
<p>武田已与 Iambic 达成多年合作伙伴关系，利用其人工智能药物发现模型推进小分子项目，交易金额可能超过 17 亿美元。</p>
<p>武田与 Iambic 的人工智能药物发现合作最初将集中在肿瘤学和胃肠治疗领域，以及炎症领域的项目上。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: Bicycle Therapeutics Plc 的 BT-1718</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: Sanofi 的 Tusamitamab ravtansine</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>通过这一安排，武田将获得 Iambic 的 NeuralPLexer 模型，以预测蛋白质 - 配体复合物。</p>
<p>该合作旨在利用 Iambic 的人工智能模型和自动化湿实验室能力推进多个高优先级的小分子项目。</p>
<p>根据协议，Iambic 将有资格获得预付款、研究费用贡献、技术访问费、成功支付（可能超过 17 亿美元），以及任何最终产品净销售的版税。</p>
<p>Iambic 的联合创始人兼首席执行官汤姆·米勒表示：“我们与武田的合作是一个强有力的机会，可以应用我们的人工智能驱动的发现和开发平台，我们很高兴能与他们的团队合作，快速推进新的更好的药物候选。”</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>来自 GlobalData</p>
<p>了解更多关于战略情报</p>
<p>“这一合作进一步验证了我们行业领先的技术，突显了我们发现能力的广度以及我们可以运作的规模。”</p>
<p>武田首席科学官兼研究负责人克里斯·阿伦特表示：“我们很高兴能够访问 Iambic 的专有计算平台，同时与他们的团队合作开发有潜力解决关键未满足患者需求的小分子治疗药物。”</p>
<p>“在武田，我们的重点是通过利用尖端科学，包括最新的人工智能进展，加速影响深远的新药物的开发。Iambic 的小分子平台与这一目标一致，并提供降低候选选择风险、提高成功概率以及更快推进选定项目从早期项目启动到 IND（临床试验新药）的潜力。”</p>
<p>上个月，武田 宣布与 Halozyme 达成全球合作 和许可协议，以继续推进 vedolizumab 与后者的 Enhanze 药物递送技术。</p>

4502

<p>泰凯达与 Iambic 建立了为期多年的合作伙伴关系，利用其人工智能药物发现模型进行小分子项目，交易金额可能超过 17 亿美元。此次合作将重点关注肿瘤学、胃肠道和炎症项目，使泰凯达能够使用 Iambic 的 NeuralPLexer 模型来预测蛋白质 - 配体复合物。Iambic 将获得预付款、研究贡献、技术费用以及最终产品的版税。两家公司旨在利用先进的人工智能技术加速新疗法的开发</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-10-02-2026-shutterstock_2427838693-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-10-02-2026-shutterstock_2427838693-430x241.jpg"/></p>
<p>Through this arrangement, Takeda will gain access to NeuralPLexer, Iambic’s model for predicting protein-ligand complexes. Credit: Veroniksha / Shutterstock.com.</p>
<div class="lb-trans"><p>通过这一安排，武田将获得 Iambic 的 NeuralPLexer 模型，以预测蛋白质 - 配体复合物。来源：Veroniksha / Shutterstock.com。</p>
</div><p>Takeda has entered a multi-year partnership to utilise Iambic’s AI drug discovery models for advancing small molecule programmes, in a deal that could exceed $1.7bn.</p>
<div class="lb-trans"><p>武田已与 Iambic 达成多年合作伙伴关系，利用其人工智能药物发现模型推进小分子项目，交易金额可能超过 17 亿美元。</p>
</div><p>The Takeda-Iambic AI drug discovery collaboration will initially focus on projects in oncology and gastrointestinal therapeutic area, as well as that of inflammation.</p>
<div class="lb-trans"><p>武田与 Iambic 的人工智能药物发现合作最初将集中在肿瘤学和胃肠治疗领域，以及炎症领域的项目上。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: Bicycle Therapeutics Plc's BT-1718</h4>
<div class="lb-trans"><h4>NPVM: Bicycle Therapeutics Plc 的 BT-1718</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: Sanofi's Tusamitamab ravtansine</h4>
<div class="lb-trans"><h4>NPVM: Sanofi 的 Tusamitamab ravtansine</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>Through this arrangement, Takeda will gain access to Iambic’s model for predicting protein-ligand complexes, NeuralPLexer.</p>
<div class="lb-trans"><p>通过这一安排，武田将获得 Iambic 的 NeuralPLexer 模型，以预测蛋白质 - 配体复合物。</p>
</div><p>The partnership aims to advance several high-priority small molecule programmes using Iambic’s AI models and automated wet lab capabilities.</p>
<div class="lb-trans"><p>该合作旨在利用 Iambic 的人工智能模型和自动化湿实验室能力推进多个高优先级的小分子项目。</p>
</div><p>Under the deal, Iambic will be eligible for upfront payments, research cost contributions, technology access fees, success-based payments potentially exceeding $1.7bn, plus royalties on net sales of any resulting products.</p>
<div class="lb-trans"><p>根据协议，Iambic 将有资格获得预付款、研究费用贡献、技术访问费、成功支付（可能超过 17 亿美元），以及任何最终产品净销售的版税。</p>
</div><p>Iambic co-founder and CEO Tom Miller said: “Our collaboration with Takeda is a powerful opportunity to apply our AI-driven discovery and development platform, and we are excited to partner with their team to quickly advance new and better drug candidates.</p>
<div class="lb-trans"><p>Iambic 的联合创始人兼首席执行官汤姆·米勒表示：“我们与武田的合作是一个强有力的机会，可以应用我们的人工智能驱动的发现和开发平台，我们很高兴能与他们的团队合作，快速推进新的更好的药物候选。”</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>来自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>“This collaboration further validates our industry-leading technology and highlights both the breadth of our discovery capabilities and the scale at which we can operate.”</p>
<div class="lb-trans"><p>“这一合作进一步验证了我们行业领先的技术，突显了我们发现能力的广度以及我们可以运作的规模。”</p>
</div><p>Takeda chief scientific officer and research head Chris Arendt said: “We are excited to be able access Iambic’s proprietary computational platform while we work with their team to develop small molecule therapeutics with the potential to address critical unmet patient needs.</p>
<div class="lb-trans"><p>武田首席科学官兼研究负责人克里斯·阿伦特表示：“我们很高兴能够访问 Iambic 的专有计算平台，同时与他们的团队合作开发有潜力解决关键未满足患者需求的小分子治疗药物。”</p>
</div><p>“At Takeda, our focus is on accelerating the development of impactful new medicines by leveraging cutting-edge science, including the latest advances in artificial intelligence. Iambic’s small molecule platform aligns with this ambition and offers the potential to de-risk candidate selection, improve the probability of success, and more quickly advance select programmes from early project start to IND [investigational new drug].”</p>
<div class="lb-trans"><p>“在武田，我们的重点是通过利用尖端科学，包括最新的人工智能进展，加速影响深远的新药物的开发。Iambic 的小分子平台与这一目标一致，并提供降低候选选择风险、提高成功概率以及更快推进选定项目从早期项目启动到 IND（临床试验新药）的潜力。”</p>
</div><p>Last month, Takeda announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the latter’s Enhanze drug delivery technology.</p>
<div class="lb-trans"><p>上个月，武田 宣布与 Halozyme 达成全球合作 和许可协议，以继续推进 vedolizumab 与后者的 Enhanze 药物递送技术。</p>
</div>

武田药品和 Iambic 宣布达成 17 亿美元的协议，以推动小分子项目的发展